Compare Aventis Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ASTRAZENECA PHARMA - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ASTRAZENECA PHARMA SANOFI INDIA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 35.1 73.6 47.6% View Chart
P/BV x 6.1 20.7 29.6% View Chart
Dividend Yield % 1.4 0.0 -  

Financials

 SANOFI INDIA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
ASTRAZENECA PHARMA
Mar-18
SANOFI INDIA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs6,8401,278 535.2%   
Low Rs4,630883 524.6%   
Sales per share (Unadj.) Rs1,203.1228.4 526.8%  
Earnings per share (Unadj.) Rs165.310.4 1,594.6%  
Cash flow per share (Unadj.) Rs209.916.3 1,290.6%  
Dividends per share (Unadj.) Rs84.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs963.698.8 975.6%  
Shares outstanding (eoy) m23.0325.00 92.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.84.7 100.8%   
Avg P/E ratio x34.7104.2 33.3%  
P/CF ratio (eoy) x27.366.4 41.1%  
Price / Book Value ratio x6.010.9 54.4%  
Dividend payout %50.80-   
Avg Mkt Cap Rs m132,07827,008 489.0%   
No. of employees `0003.31.4 243.4%   
Total wages/salary Rs m4,0681,535 265.0%   
Avg. sales/employee Rs Th8,393.84,210.9 199.3%   
Avg. wages/employee Rs Th1,232.41,132.2 108.8%   
Avg. net profit/employee Rs Th1,153.0191.1 603.4%   
INCOME DATA
Net Sales Rs m27,7085,710 485.3%  
Other income Rs m897123 732.2%   
Total revenues Rs m28,6055,833 490.4%   
Gross profit Rs m6,235463 1,346.9%  
Depreciation Rs m1,027147 696.7%   
Interest Rs m70-   
Profit before tax Rs m6,098438 1,392.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,292179 1,281.2%   
Profit after tax Rs m3,806259 1,468.9%  
Gross profit margin %22.58.1 277.6%  
Effective tax rate %37.640.8 92.0%   
Net profit margin %13.74.5 302.7%  
BALANCE SHEET DATA
Current assets Rs m15,9223,209 496.1%   
Current liabilities Rs m6,2352,070 301.3%   
Net working cap to sales %35.020.0 175.2%  
Current ratio x2.61.6 164.7%  
Inventory Days Days6472 88.0%  
Debtors Days Days2135 59.8%  
Net fixed assets Rs m7,539790 953.9%   
Share capital Rs m23050 460.0%   
"Free" reserves Rs m21,9622,419 907.8%   
Net worth Rs m22,1922,469 898.7%   
Long term debt Rs m00-   
Total assets Rs m29,8394,605 647.9%  
Interest coverage x872.1NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.2 74.9%   
Return on assets %12.85.6 227.1%  
Return on equity %17.210.5 163.4%  
Return on capital %27.517.7 155.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,587300 2,532.8%   
Fx outflow Rs m7,1452,015 354.6%   
Net fx Rs m442-1,715 -25.8%   
CASH FLOW
From Operations Rs m3,73988 4,253.7%  
From Investments Rs m-731-94 781.0%  
From Financial Activity Rs m-1,972NA-  
Net Cashflow Rs m1,036-6 -18,175.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 0.3 4,800.0%  
FIIs % 14.6 15.7 93.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 9.1 115.4%  
Shareholders   15,184 12,856 118.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare SANOFI INDIA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 20, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS